Funding for this research was provided by:
Austrian Science Fund (KLI341)
Paracelsus Medical University Salzburg (A-14/01/010-BWA)
Text and Data Mining valid from 2018-11-01
Received: 17 September 2018
Accepted: 22 October 2018
First Online: 1 November 2018
Ethics approval and consent to participate
: Authors declare that this work received all necessary ethical approvals and that patients involved all consented to participate. This study was reviewed and approved by Salzburg IRB; approval 415-E/1619/28–2016.DRKS. DRKS00005412. Registered 6 November 2013, ExternalRef removed
: Not applicable.
: Verena Wally and Johann W. Bauer own shares of the company Diaderm, which receives license payments from Castle Creek Pharma (CCP). CCP is conducting a Phase 2/3 study with a diacerein-containing ointment (NCT03154333).Johann W. Bauer was holder of the EMA orphan drug designation on diacerein in epidermolysis bullosa.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.